XPR – Lifestyle Demo
Author:
Evaxion
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
May 12, 2026
Evaxion announces business update and first quarter 2026 financial results
May 7, 2026
Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026
May 4, 2026
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer
April 27, 2026
New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma
April 17, 2026
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
April 17, 2026
Evaxion concludes Annual General Meeting
April 16, 2026
Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01
April 7, 2026
Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress
March 30, 2026
Notice to convene Evaxion’s Annual General Meeting
March 19, 2026
1
2
Next Page
→